# Generate Biomedicines

**Source:** https://geo.sig.ai/brands/generate-biomedicines  
**Vertical:** Healthcare Tech  
**Subcategory:** AI Drug Discovery & Generative Biology  
**Tier:** Challenger  
**Website:** generatebiomedicines.com  
**Last Updated:** 2026-04-14

## Summary

Generative biology biotech using AI to design protein therapeutics. IPO'd on Nasdaq (GENB) Feb 2026, raising $400M. Lead drug GB-0895 in Phase 3 for severe asthma.

## Company Overview

Generate Biomedicines is a clinical-stage biotech founded in 2018 by Flagship Pioneering, headquartered in Somerville, Massachusetts. The company pioneers generative biology, using ML and large-scale experimental systems to design protein therapeutics. Its platform combines diffusion and graph-based AI models with high-throughput biohardware. The pipeline spans immunology, oncology, and infectious diseases.

Generate's model combines internal drug development with collaboration revenue from Amgen and Novartis. Lead program GB-0895, a long-acting anti-TSLP antibody engineered for every-six-month dosing, is in Phase 3 for severe asthma with FDA Fast Track designation (January 2026). It competes with Recursion Pharmaceuticals and Absci.

Generate went public on Nasdaq in February 2026 under ticker GENB, raising approximately $400 million. 2025 collaboration revenue was $31.89 million against a $222.97 million net loss. With 312 employees, the company is advancing its Phase 3 program and expanding its generative biology platform.

## Frequently Asked Questions

### What is Generate Biomedicines?
A clinical-stage biotech using generative AI to design protein therapeutics, founded by Flagship Pioneering in 2018.

### Is Generate Biomedicines publicly traded?
Yes, on Nasdaq under ticker GENB since February 2026, raising $400M in its IPO at $16/share.

### What is GB-0895?
Lead anti-TSLP antibody in Phase 3 for severe asthma, engineered for every-six-month dosing with FDA Fast Track designation.

### Who are Generate's pharma partners?
Amgen and Novartis, generating $31.89 million in collaboration revenue in 2025.

### How does Generate's AI platform work?
Combines diffusion and graph-based AI models with high-throughput biohardware in a design-build-test-learn cycle to generate therapeutic protein candidates.

### How does Generate Biomedicines' generative AI platform differ from other biotech AI approaches?
Generate's platform uses protein language models and diffusion models to generate novel protein sequences with desired therapeutic properties from scratch — a true generative approach rather than screening or optimizing known molecules. This allows the company to explore regions of protein space that evolution never reached, potentially accessing new antibody binding modes and therapeutic mechanisms unavailable through traditional discovery methods.

### What is Generate's lead clinical program and its significance?
GB-0895 is an anti-TSLP antibody in Phase 3 trials for severe asthma, engineered with extended half-life properties enabling every-six-month subcutaneous dosing — vs. monthly dosing for competing biologics. If approved, this dosing convenience could differentiate it significantly from AstraZeneca's Tezspire and GSK's Nucala in the competitive severe asthma market, demonstrating the clinical value of generatively engineered protein properties.

### What did Generate Biomedicines' IPO reveal about its financials?
Generate Biomedicines raised $400 million in its February 2026 Nasdaq IPO (ticker GENB) at $16/share. The prospectus revealed $31.89 million in collaboration revenue in 2025 from Amgen and Novartis partnerships, ongoing Phase 3 clinical expenses for GB-0895, and a cash runway extending through 2028. The company remains pre-product revenue, with all near-term income coming from partnership milestones and research collaborations.

## Tags

b2b, healthtech, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*